Our Q3 2010 report detailed several significant catalysts that resulted in double-digit stock price changes, details of which can be found in the table on Page 2 of this report.

Our Q4 2010 report covers a number of catalysts from 21 drugs, one device and one diagnostic, highlighted by news in the cardiovascular, metabolic and Hepatitis C spaces. Additionally, we have included comprehensive calendars for the remainder of 2010 from our sister product, CatalystTracker, of Large Impact catalysts in the drug, device/diagnostic and natural resource areas.

For the full report, please download the PDF version at the top of this page.

For our disclosures, please read the BioMedTracker Research Standards.